Q-line Biotech
Spreading Healthiness!

Date: 12-11-2026

To,
The Listing Department
National Stock Exchange of India Limited,
"Exchange Plaza" 5th Floor, Plot No. C-1, G Block,
Bandra Kurla Complex, Bandra (East), Mumbai – 400051

NSE Symbol: QLINE ISIN-INE1G2W01011

Subject: Press Release on Financial Highlights for the Half Year ended 30th September 2026

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 please find enclosed press release on financial highlights for the half year ended 30th September 2026. The same is also being uploaded on the Company's website at: **www.qlinebiotech.com.**

Thanking You,

For Q Line Biotech Limited

SAURABH GARG
Digitally signed by SAURABH GARG
Date: 2026.11.12 19:55:44 +05'30'

Saurabh Garg
Chairman & Managing Director
DIN: 02891621

Q-LINE BIOTECH LIMITED

Unaudited Financial Results for the Half Year Ended September 30, 2026 (H1 FY27)

H1 FY27 vs H1 FY26: **Revenue +5.83% | EBITDA +10.02% | EBITDA Margin 26.00% (+99 bps)**

H1 FY27	₹15,218 lakhs Revenue ▲ 5.83%	₹3,957 lakhs EBITDA ▲ 10.02%	₹1,960 lakhs PAT ▼ 8.06%

Lucknow, November 12, 2026: Q-Line Biotech Limited, a leading manufacturer of diagnostic test kits, reagents and laboratory equipment in India, today announced its unaudited financial results for the half year ended 30th September 2026. Headquartered in Lucknow and promoted by the Garg family, which brings over 31 years of experience in the diagnostics industry, the Company serves diagnostic laboratories and hospitals across 26 states through its extensive distribution network. The Company delivered a resilient operating performance during the half year, with EBITDA growth outpacing revenue growth, driven by sustained demand for its products, expanding market presence and continued focus on operational excellence.

The Board of Directors, at its meeting held on November 12, 2026, approved the unaudited consolidated financial results for the half year ended September 30, 2026.

Financial Performance Summary

Consolidated Financial Performance – H1 FY27 vs H1 FY26 *(₹ in lakhs)*

Particulars	H1 FY27	H1 FY26	YoY (%)	FY26
Total Revenue*	**15,217.75**	14,379.81	5.83%	34,173.57
EBITDA**	**3,957.19**	3,596.70	10.02%	9,804.54
Profit Before Tax***	**2,593.97**	2,624.58	-1.17%	7,354.15
Profit After Tax***	**1,959.89**	2,131.62	-8.06%	5,671.34

**Total Revenue = Revenue from Operations (excluding Other Income).*

***EBITDA = Profit before extraordinary items, prior period items and tax + Finance costs + Depreciation & amortization – Other income.*

****PBT and PAT are before extraordinary items (₹99.17 lakh in H2 FY26; nil in H1 FY27 and H1 FY26).*

H1 FY27 – Steady Growth with Improved Operating Margins

H1 FY27 reflected steady business momentum, with EBITDA growth outpacing revenue growth and operating margins improving year-on-year, driven by strong growth in reagent sales, expansion in the trade business and continued focus on operational efficiencies.

Particulars	H1 FY27 vs H1 FY26 Growth	H1 FY27 Margin (% of Revenue H1 FY27)
Total Revenue	**+5.83%**	—
EBITDA	**+10.02%**	*EBITDA Margin* 26.00%
Profit Before Tax	**-1.17%**	*PBT Margin* 17.05%
Profit After Tax	**-8.06%**	*PAT Margin* 12.88%

Key Financial Highlights — H1 FY27 vs H1 FY26

- Revenue Growth: Total revenue increased by **5.83%** for the half year to ₹152.18 crore in H1 FY27, compared with ₹143.80 crore in H1 FY26.
- EBITDA Growth: EBITDA grew by **10.02%** for the half year to ₹39.57 crore, outperforming revenue growth.
- Margin Expansion: EBITDA margin improved to **26.00%** from 25.01% in the corresponding period last year, an expansion of 99 basis points.
- Profit Before Tax: PBT stood at ₹25.94 crore compared with ₹26.25 crore in H1 FY26, a marginal decline of 1.17%.
- Profit After Tax: PAT stood at ₹19.60 crore compared with ₹21.32 crore in H1 FY26, a decline of 8.06%.

Performance Overview

- Q-Line Biotech delivered growth in its operating performance during H1 FY27, with EBITDA growth outpacing revenue growth. The improvement in EBITDA margin from 25.01% to 26.00% reflects stronger operating-level profitability.
- The growth in the trade business and reagent segment, alongside stable government-order revenue, represents important elements of the Company's business performance during the period.
- Profit before tax was broadly stable, while PAT was lower than in H1 FY26. This was mainly due to higher depreciation (₹7.89 crore vs ₹4.09 crore) following the capitalisation of Unit 4 and higher finance costs (₹9.84 crore vs ₹8.31 crore), partly offset by higher other income (₹4.09 crore vs ₹2.67 crore). H1 FY26 PAT also included a write-back of earlier years' tax of ₹1.95 crore, which did not recur in H1 FY27. PBT margin declined to 17.05% from 18.25%, while PAT margin stood at 12.88% compared with 14.82% in H1 FY26.

- The Company remains focused on strengthening its financial performance, expanding its domestic trade and export business, CDMO capabilities increasing reagent sales and enhancing overall profitability.

Revenue Mix and Business Performance

- During H1 FY27, Q-Line Biotech continued to strengthen its trade business, which recorded growth of 20.13% compared with H1 FY26. This performance reflects increasing traction in the Company's trade channel and progress in expanding its market reach.
- Revenue from government orders remained stable compared with the corresponding period last year, providing continuity to the Company's institutional business.
- At the product level, reagent revenue registered strong half year growth of 19.23%, highlighting the continued strength of the Company's consumables business and recurring revenue potential.
- Instrument revenue declined by 29.71% in the half year, primarily due to the non-availability of consignees for government orders in hand, which affected the execution and delivery of instrument supplies during the period.
- The Company continues to focus on strengthening its trade distribution network within India and overseas, expanding reagent sales and improving the execution of institutional and government orders.

Key Business Developments

- Manufacturing Expansion: The Company has made significant progress in operationalising its new manufacturing facility, Unit 4. While the regulatory approval process took longer than initially anticipated, the Company had obtained 9 product licences as of September 30, 2026. Subsequently, through continued engagement with the regulatory authorities, the Company has successfully increased the number of product licences to 36 as on date, with additional licences currently under various stages of approval. With a substantial number of regulatory approvals now in place, the Company expects to progressively scale up manufacturing operations and believes that the facility will become fully operational during H2 FY27. The new facility is expected to significantly strengthen the Company's in-house manufacturing capabilities, enhance production capacity and support the growing demand for its diagnostic reagents and kits.
- International Expansion: As part of its global growth strategy, Q-Line Biotech has been actively strengthening its international business operations and expanding its export footprint. The Company appointed two International Business Managers to accelerate business development and strengthen its global distribution network. Leveraging its international distribution partnerships, the Company had envisaged nearly 5X growth in export revenues in FY27. However, the planned scale-up of international business may take longer than initially anticipated due to prevailing geopolitical uncertainties in West Asia, which have resulted in supply-chain disruptions, logistical challenges and delays in international trade movements.
- While these developments may impact the pace of export business expansion in the near term, the Company remains committed to strengthening its international presence and building a sustainable export business

over the medium to long term. The Company will continue to engage with its international distribution partners and pursue export opportunities as market and supply-chain conditions improve.

- The Company has successfully launched the Microlab 300 under its "Make in India" initiative and has commenced commercial sales, with initial units already sold.

- The Company intends to commence CDMO operations through the manufacture of Selectra Pro M and Microlab 300 instruments. Under its exclusive technical collaboration arrangement, these instruments will be exported to the principal company, enabling the Company to leverage its manufacturing capabilities for international markets while continuing to serve the Indian market.The Company will intensify the business development efforts in CDMO vertical

- The Company has launched a new range of Molecular Detection Testing Kits for the detection of Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV), including a combined three-in-one testing solution for infectious disease screening in blood banks.

- These newly launched products represent an important addition to the Company's Molecular Diagnostics portfolio and strengthen its offerings in the infectious disease screening segment. The launch further expands Q-Line Biotech's product capabilities and enables the Company to address the growing requirements of blood banks and healthcare institutions for advanced molecular diagnostic solutions.

Corporate Restructuring and Business Consolidation

- As part of its long-term strategic vision, the Board has approved the consolidation of one of its group companies “Heidelco Medicore Private Limited” under Q-Line Biotech Limited, the listed flagship entity of the Group by acquiring a 70% equity stake in Heidelco Medicore Private Limited. This proposed consolidation is aimed at streamlining the Group's corporate structure, bringing relevant business operations under a unified platform and strengthening operational and administrative efficiencies.

- Heidelco has demonstrated strong financial growth over the last two financial years. Its revenue from operations increased from ₹50.91 crore in FY24 to ₹108.18 crore in FY26, while Profit After Tax grew from ₹3.11 crore to ₹7.91 crore during the same period. Under the proposed transaction, Q-Line Biotech Limited intends to acquire 5,25,000 equity shares, representing 70% of the equity share capital of Heidelco, from Mr. Saurabh Garg for an aggregate consideration of ₹26.63 crore. The consideration has been determined based on Heidelco’s Net Asset Value (NAV) and will be funded through general corporate purpose portion of IPO and balance through internal accruals.

Management Commentary

Commenting on the results, Mr. Saurabh Garg, Managing Director & Chairman, Q-Line Biotech Limited, said:
H1 FY27 has been a period of continued strategic progress for Q-Line Biotech Limited, as we remain focused on strengthening our core business, expanding our product portfolio and building a more diversified and sustainable growth platform. During the first half of the year, our revenue grew by 5.83%, while EBITDA increased by 10.02%, with EBITDA margins improving to 26.00% from 25.01% in the corresponding period last year.

The decline in Profit After Tax during H1 FY27 was primarily attributable to the higher depreciation charge following the capitalization of the Company's new manufacturing facility, Unit 4 (C-42), in Q4 FY26. With the facility now capitalized, the depreciation expense has increased during the current period, impacting reported profitability. The comparison is also affected by a one-time write-back of earlier years' tax of ₹1.95 crore in H1 FY26. The Company expects the new facility to progressively contribute to business growth as manufacturing operations scale up, with the objective of improving capacity utilization and generating long-term operating benefits.

We witnessed encouraging growth of 19.23% in our reagent business and 20.13% in our trade business, reflecting the increasing traction of our distribution network and the underlying strength of our consumable's portfolio. Our government business remained stable compared with the corresponding period last year. However, instrument revenues were impacted by a decline of 29.71%, primarily due to the non-availability of consignees for certain government orders, which affected the execution and delivery of supplies during the period. We remain engaged in strengthening our institutional relationships and improving order execution.

A key priority continues to be the expansion of our manufacturing capabilities. While the regulatory approval process for our new manufacturing facility, Unit 4, took longer than initially anticipated, we have made significant progress, increasing the number of product licenses from 9 as of September 30, 2026 to 36 as of November 5, 2026. We expect the facility to become fully operational during H2 FY27, which will further strengthen our manufacturing capabilities and support our future growth.

We are also pursuing strategic initiatives to broaden our business portfolio and strengthen our overall healthcare ecosystem, including the proposed acquisition of a majority stake in Heidelco Medicore Private Limited. This initiative is aimed at bringing complementary healthcare businesses under our listed entity, creating opportunities for cross-selling, distribution synergies and future expansion.

As we move into the second half of FY27, our priorities remain clear: scaling up manufacturing at Unit 4, accelerating reagent and trade business growth, improving instrument sales execution, expanding our molecular diagnostics portfolio and strengthening our international presence. We remain confident that the investments and strategic initiatives undertaken by the Company will strengthen our business fundamentals and create sustainable long-term value for our shareholders."

About Q-Line Biotech Limited

Q-Line Biotech Limited is engaged in the development, manufacturing, and marketing of diagnostic reagents, kits, point-of-care (POC) devices, consumables, and in-vitro diagnostic (IVD) equipment. Since 2013, the Company has been serving diagnostic laboratories, hospitals, and medical colleges across India through a direct and distributor-led network.

Over the past decade years, the Company has established a strong presence in the IVD industry through its manufacturing capabilities, research & development expertise, and quality-focused approach. Its product portfolio spans key diagnostic segments, including Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics, and POC Devices & Rapid Tests.

The Company further strengthened its capabilities during the COVID-19 pandemic by developing and commercializing a range of testing solutions, including RT-PCR Kits, RNA Extraction Kits, and VTM Kits, leveraging both in-house R&D and strategic technical collaborations.

For More Details Visit: www.qlinebiotech.com

Contact Us:

Q-Line Biotech Limited	Stellar IR Advisors Pvt. Ltd.
Akhand Pratap Singh – Compliance Officer compliance@qlinebiotech.com	Ankit Jain | ankit@stellar-ir.com Manveer Sharma | manveer@stellar-ir.com
Contact no.: 005 222 435570	Contact no.: +91 22 62398024

Safe Harbour Statement: *Statements in this release describing the Company's objectives, projections, estimates and expectations may be "forward looking statements" within the meaning of applicable laws and regulations. Actual results may differ materially from those expressed or implied. The Company assumes no obligation to update any forward-looking statements that may be made from time to time.*